Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Hepatitis C | Research article

Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study

Authors: Alicja E. Grzegorzewska, Adrianna Mostowska, Monika K. Świderska, Wojciech Marcinkowski, Ireneusz Stolarek, Marek Figlerowicz, Paweł P. Jagodziński

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

In non-uremic subjects, IFNL4 rs368234815 predicts HCV clearance. We investigated whether rs368234815 is associated with spontaneous HCV clearance in haemodialysis patients and whether it is a stronger predictor of HCV resolution than the IFNL polymorphisms already associated with HCV clearance in dialysis subjects. We also evaluated an association of rs368234815 with patients` survival and alterations in transcription factor binding sites (TFBS) caused by IFNL polymorphisms.

Methods

Among 161 haemodialysis patients with positive anti-HCV antibodies, 68 (42.2%) spontaneously resolved HCV infection, whereas 93 remained HCV RNA positive. Patients were tested for near IFNL3 rs12980275, IFNL3 rs4803217, IFNL4 rs12979860, IFNL4 rs368234815, and near IFNL4 rs8099917. IFNL4 rs368234815 polymorphism (TT/TT, ΔG/TT, ΔG/ΔG) was genotyped by restriction fragment length polymorphism analysis; other IFNL polymorphisms - by high resolution melting curve analysis. We used the Kaplan-Meier method with the log-rank test for survival analysis. In silico analysis included the use of ENCODE TFBS ChIP-seq data, HOCOMOCO, JASPAR CORE, and CIS-BP databases, and FIMO software.

Results

The probability (OR, 95%CI, P) of spontaneous HCV clearance for rs368234815 TT/TT patients was higher than for the ΔG allele carriers (2.63, 1.38–5.04, 0.003). This probability for other major homozygotes varied between 2.80, 1.45–5.43, 0.002 for rs12980275 and 2.44, 1.27–4.69, 0.007 for rs12979860. In the additive model, rs368234815 TT/TT was the strongest predictor of HCV clearance (6.38, 1.69–24.2, 0.003). Survival analysis suggested an association of the ΔG allele with mortality due to neoplasms (log-rank P = 0.005). The rs368234815 ∆G allele caused TFBS removal for PLAGL1.

Conclusions

In haemodialysis patients, the association of rs368234815 with the spontaneous HCV clearance is better than that documented for other IFNL3/IFNL4 polymorphisms only in the additive mode of inheritance. However, identifying the homozygosity in the variant ∆G allele of rs368234815 means a more potent prediction of persistent HCV infection in haemodialysis subjects that we observe in the case of the variant homozygosity of other tested IFNL3/IFNL4 polymorphisms. Removal of PLAGL1 TFBS in subjects harbouring the rs368234815 ∆G allele may contribute to cancer susceptibility. The association of rs368234815 with cancer-related mortality needs further studies in HCV-exposed subjects.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.PubMedCrossRef Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.PubMedCrossRef
2.
go back to reference Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–8.PubMedCrossRef Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–8.PubMedCrossRef
3.
go back to reference Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep. 2015;5:16037.PubMedPubMedCentralCrossRef Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep. 2015;5:16037.PubMedPubMedCentralCrossRef
4.
go back to reference Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.PubMedCrossRef Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.PubMedCrossRef
5.
go back to reference Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577–85.PubMedCrossRef Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577–85.PubMedCrossRef
7.
go back to reference Rauch A, Kutalik Z, Descombes P, et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338–45.PubMedCrossRef Rauch A, Kutalik Z, Descombes P, et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338–45.PubMedCrossRef
8.
go back to reference Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49:1853–60.PubMedPubMedCentralCrossRef Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49:1853–60.PubMedPubMedCentralCrossRef
9.
go back to reference Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164–71.PubMedPubMedCentralCrossRef Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164–71.PubMedPubMedCentralCrossRef
10.
go back to reference Murakawa M, Asahina Y, Nakagawa M, et al. Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J Gastroenterol Hepatol. 2015;30:1075–84.PubMedCrossRef Murakawa M, Asahina Y, Nakagawa M, et al. Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J Gastroenterol Hepatol. 2015;30:1075–84.PubMedCrossRef
11.
go back to reference Ferraris P, Chandra PK, Panigrahi R, et al. Cellular mechanism for impaired hepatitis C virus clearance by interferon associated with IFNL3 gene polymorphisms relates to intrahepatic interferon-λ expression. Am J Pathol. 2016;186:938–51.PubMedPubMedCentralCrossRef Ferraris P, Chandra PK, Panigrahi R, et al. Cellular mechanism for impaired hepatitis C virus clearance by interferon associated with IFNL3 gene polymorphisms relates to intrahepatic interferon-λ expression. Am J Pathol. 2016;186:938–51.PubMedPubMedCentralCrossRef
12.
go back to reference Price AA, Tedesco D, Prasad MR, et al. Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype. Proc Natl Acad Sci U S A. 2016;113:10678–83.PubMedPubMedCentralCrossRef Price AA, Tedesco D, Prasad MR, et al. Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype. Proc Natl Acad Sci U S A. 2016;113:10678–83.PubMedPubMedCentralCrossRef
13.
go back to reference Keshvari M, Alavian SM, Behnava B, Pouryasin A, Sharafi H. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. J Res Med Sci. 2016;21:72.PubMedPubMedCentralCrossRef Keshvari M, Alavian SM, Behnava B, Pouryasin A, Sharafi H. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. J Res Med Sci. 2016;21:72.PubMedPubMedCentralCrossRef
14.
go back to reference Aka PV, Kuniholm MH, Pfeiffer RM, et al. Association of the IFNL4-ΔG allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis. 2014;209:350–4.PubMedCrossRef Aka PV, Kuniholm MH, Pfeiffer RM, et al. Association of the IFNL4-ΔG allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis. 2014;209:350–4.PubMedCrossRef
15.
go back to reference Bibert S, Roger T, Calandra T, et al. Swiss hepatitis C cohort study. IL28B expression depends on a novel TT/−G polymorphism which improves HCV clearance prediction. J Exp Med. 2013;210:1109–16.PubMedPubMedCentralCrossRef Bibert S, Roger T, Calandra T, et al. Swiss hepatitis C cohort study. IL28B expression depends on a novel TT/−G polymorphism which improves HCV clearance prediction. J Exp Med. 2013;210:1109–16.PubMedPubMedCentralCrossRef
16.
go back to reference Franco S, Aparicio E, Parera M, Clotet B, Tural C, Martinez MA. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS. 2014;28:133–6.PubMedCrossRef Franco S, Aparicio E, Parera M, Clotet B, Tural C, Martinez MA. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS. 2014;28:133–6.PubMedCrossRef
17.
go back to reference Rugwizangoga B, Andersson ME, Kabayiza JC, et al. IFNL4 genotypes predict clearance of RNA viruses in Rwandan children with upper respiratory tract infections. Front Cell Infect Microbiol. 2019;9:340.PubMedPubMedCentralCrossRef Rugwizangoga B, Andersson ME, Kabayiza JC, et al. IFNL4 genotypes predict clearance of RNA viruses in Rwandan children with upper respiratory tract infections. Front Cell Infect Microbiol. 2019;9:340.PubMedPubMedCentralCrossRef
18.
go back to reference O'Brien TR, Pfeiffer RM, Paquin A, et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol. 2015;63:1103–10.PubMedPubMedCentralCrossRef O'Brien TR, Pfeiffer RM, Paquin A, et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol. 2015;63:1103–10.PubMedPubMedCentralCrossRef
19.
go back to reference Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.PubMedCrossRef Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.PubMedCrossRef
20.
go back to reference Xie X, Zhang L, Chen YZ. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: a meta-analysis. Hum Immunol. 2016;77:609–15.PubMedCrossRef Xie X, Zhang L, Chen YZ. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: a meta-analysis. Hum Immunol. 2016;77:609–15.PubMedCrossRef
21.
go back to reference Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014;209(11):1700–4.PubMedCrossRef Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014;209(11):1700–4.PubMedCrossRef
22.
go back to reference Sung PS, Shin EC. Interferon response in hepatitis C virus-infected hepatocytes: issues to consider in the era of direct-acting antivirals. Int J Mol Sci. 2020;21(7):2583.PubMedCentralCrossRef Sung PS, Shin EC. Interferon response in hepatitis C virus-infected hepatocytes: issues to consider in the era of direct-acting antivirals. Int J Mol Sci. 2020;21(7):2583.PubMedCentralCrossRef
23.
go back to reference Zedan HE, Talaat RM, Ammar AAA, Sakr MA. Interferon-lambda 4 gene polymorphisms predict treatment response in Egyptian HCV genotype 4 patients exposed to radiation. Egypt J Hosp Med. 2019;77(1):4748–53. Zedan HE, Talaat RM, Ammar AAA, Sakr MA. Interferon-lambda 4 gene polymorphisms predict treatment response in Egyptian HCV genotype 4 patients exposed to radiation. Egypt J Hosp Med. 2019;77(1):4748–53.
24.
go back to reference Grzegorzewska AE, Jodłowska E, Mostowska A, Jagodziński P. Effect of interferon λ3 gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients. Pol Arch Med Wewn. 2015;125:894–902.PubMed Grzegorzewska AE, Jodłowska E, Mostowska A, Jagodziński P. Effect of interferon λ3 gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients. Pol Arch Med Wewn. 2015;125:894–902.PubMed
25.
go back to reference Dzekova-Vidimliski P, Nikolov IG, Matevska-Geshkovska N, Mena S, Rostaing L, Dimovski A, Sikole A. Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients. Ren Fail. 2015;37:1180–4.PubMedCrossRef Dzekova-Vidimliski P, Nikolov IG, Matevska-Geshkovska N, Mena S, Rostaing L, Dimovski A, Sikole A. Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients. Ren Fail. 2015;37:1180–4.PubMedCrossRef
26.
go back to reference Grzegorzewska AE, Winnicka H, Warchoł W, Marcinkowski W, Mostowska A, Jagodziński PP. Effects of interferon-λ3 gene polymorphic variants in response to HBV vaccination and outcome of HBV and HCV infections in hemodialysis patients. In: hemodialysis abstracts from the 39th annual Dialysis conference (Dallas). Hemodial Int. 2019;23(1):A17–8. Grzegorzewska AE, Winnicka H, Warchoł W, Marcinkowski W, Mostowska A, Jagodziński PP. Effects of interferon-λ3 gene polymorphic variants in response to HBV vaccination and outcome of HBV and HCV infections in hemodialysis patients. In: hemodialysis abstracts from the 39th annual Dialysis conference (Dallas). Hemodial Int. 2019;23(1):A17–8.
27.
go back to reference Yu ML. Dai CY, Huang CF, et al; FORMOSA-LIKE group. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. J Hepatol. 2014;60:253–9.PubMedCrossRef Yu ML. Dai CY, Huang CF, et al; FORMOSA-LIKE group. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. J Hepatol. 2014;60:253–9.PubMedCrossRef
28.
go back to reference Rukov JL, Gravesen E, Mace ML, et al. Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA-sequencing. Am J Physiol Renal Physiol. 2016;310:F477–91.PubMedPubMedCentralCrossRef Rukov JL, Gravesen E, Mace ML, et al. Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA-sequencing. Am J Physiol Renal Physiol. 2016;310:F477–91.PubMedPubMedCentralCrossRef
29.
go back to reference Pouryasin M, Sharafi H, Behnava B, Alavian SM, Keshvari M, Pouryasin A. A simple PCR-RFLP method for genotyping of IFNL4 rs368234815 polymorphism in patients with chronic hepatitis C. Lab Med. 2017;48:51–6.PubMedCrossRef Pouryasin M, Sharafi H, Behnava B, Alavian SM, Keshvari M, Pouryasin A. A simple PCR-RFLP method for genotyping of IFNL4 rs368234815 polymorphism in patients with chronic hepatitis C. Lab Med. 2017;48:51–6.PubMedCrossRef
30.
go back to reference Rosenbloom KR, Sloan CA, Malladi VS, et al. ENCODE data in the UCSC genome browser: year 5 update. Nucleic Acids Res. 2013;41:D56–63.PubMedCrossRef Rosenbloom KR, Sloan CA, Malladi VS, et al. ENCODE data in the UCSC genome browser: year 5 update. Nucleic Acids Res. 2013;41:D56–63.PubMedCrossRef
31.
go back to reference Kulakovskiy IV, Vorontsov IE, Yevshin IS, et al. HOCOMOCO: expansion and enhancement of the collection of transcription factor binding sites models. Nucleic Acids Res. 2016;44:D116–25.PubMedCrossRef Kulakovskiy IV, Vorontsov IE, Yevshin IS, et al. HOCOMOCO: expansion and enhancement of the collection of transcription factor binding sites models. Nucleic Acids Res. 2016;44:D116–25.PubMedCrossRef
32.
go back to reference Mathelier A, Fornes O, Arenillas DJ, et al. JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2016;44:D110–5.PubMedCrossRef Mathelier A, Fornes O, Arenillas DJ, et al. JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2016;44:D110–5.PubMedCrossRef
33.
35.
go back to reference Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank. Nucleic Acids Res. 2005;33:D34–8.PubMedCrossRef Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank. Nucleic Acids Res. 2005;33:D34–8.PubMedCrossRef
36.
go back to reference UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res. 2015;43:D204–12.CrossRef UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res. 2015;43:D204–12.CrossRef
37.
go back to reference Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5.PubMedCrossRef Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5.PubMedCrossRef
38.
go back to reference Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple hypothesis testing. J R Stat Soc B. 1995;57:289–300. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple hypothesis testing. J R Stat Soc B. 1995;57:289–300.
40.
go back to reference Świątek-Kościelna B, Kałużna E, Strauss E, et al. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol. 2017;23:3815–24.PubMedPubMedCentralCrossRef Świątek-Kościelna B, Kałużna E, Strauss E, et al. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol. 2017;23:3815–24.PubMedPubMedCentralCrossRef
41.
go back to reference de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martínez MA. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One. 2012;7:e31016.PubMedPubMedCentralCrossRef de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martínez MA. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One. 2012;7:e31016.PubMedPubMedCentralCrossRef
42.
go back to reference Vergara C, Duggal P, Thio CL, et al. Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. Genes Immun. 2020;21(5):348–59.PubMedCrossRefPubMedCentral Vergara C, Duggal P, Thio CL, et al. Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. Genes Immun. 2020;21(5):348–59.PubMedCrossRefPubMedCentral
43.
go back to reference Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C virus genetic variability, human immune response, and genome polymorphisms: which is the interplay? Cells. 2019;8(4):305.PubMedCentralCrossRef Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C virus genetic variability, human immune response, and genome polymorphisms: which is the interplay? Cells. 2019;8(4):305.PubMedCentralCrossRef
44.
go back to reference Obajemu AA, Rao N, Dilley KA, et al. IFN-λ4 attenuates antiviral responses by enhancing negative regulation of IFN signaling. J Immunol. 2017;199(11):3808–20.PubMedCrossRef Obajemu AA, Rao N, Dilley KA, et al. IFN-λ4 attenuates antiviral responses by enhancing negative regulation of IFN signaling. J Immunol. 2017;199(11):3808–20.PubMedCrossRef
45.
go back to reference O'Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-λ4: the paradoxical new member of the interferon lambda family. J Interf Cytokine Res. 2014;34(11):829–38.CrossRef O'Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-λ4: the paradoxical new member of the interferon lambda family. J Interf Cytokine Res. 2014;34(11):829–38.CrossRef
46.
go back to reference Chaturvedi N, Svarovskaia ES, Mo H, et al. Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. Elife. 2019;8:e42542.PubMedPubMedCentralCrossRef Chaturvedi N, Svarovskaia ES, Mo H, et al. Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. Elife. 2019;8:e42542.PubMedPubMedCentralCrossRef
47.
go back to reference Cho YK, Kim YN, Song BC. Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Clin Mol Hepatol. 2014;20(4):368–75 Erratum in: Clin Mol Hepatol. 2015;21(1):104.PubMedPubMedCentralCrossRef Cho YK, Kim YN, Song BC. Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Clin Mol Hepatol. 2014;20(4):368–75 Erratum in: Clin Mol Hepatol. 2015;21(1):104.PubMedPubMedCentralCrossRef
48.
go back to reference Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology. 2012;55(6):1684–91.PubMedCrossRef Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology. 2012;55(6):1684–91.PubMedCrossRef
49.
50.
go back to reference Tang W, Wallace TA, Yi M, et al. IFNL4-ΔG allele is associated with an interferon signature in tumors and survival of African-American men with prostate Cancer. Clin Cancer Res. 2018;24(21):5471–81.PubMedPubMedCentralCrossRef Tang W, Wallace TA, Yi M, et al. IFNL4-ΔG allele is associated with an interferon signature in tumors and survival of African-American men with prostate Cancer. Clin Cancer Res. 2018;24(21):5471–81.PubMedPubMedCentralCrossRef
51.
go back to reference Onabajo OO, Wang F, Banday R, Prokunina-Olsson L. Tumor transcriptome analysis and immune infiltrate profiling suggests a role for the IFNL3/IFNL4 genomic locus in liver cancer. J Immunol. 2018;200(1 Supplement):178. Onabajo OO, Wang F, Banday R, Prokunina-Olsson L. Tumor transcriptome analysis and immune infiltrate profiling suggests a role for the IFNL3/IFNL4 genomic locus in liver cancer. J Immunol. 2018;200(1 Supplement):178.
52.
go back to reference Lasfar A, Zloza A, Silk AW, Lee LY, Cohen-Solal KA. Interferon lambda: toward a dual role in cancer. J Interf Cytokine Res. 2019;39:22–9.CrossRef Lasfar A, Zloza A, Silk AW, Lee LY, Cohen-Solal KA. Interferon lambda: toward a dual role in cancer. J Interf Cytokine Res. 2019;39:22–9.CrossRef
Metadata
Title
Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study
Authors
Alicja E. Grzegorzewska
Adrianna Mostowska
Monika K. Świderska
Wojciech Marcinkowski
Ireneusz Stolarek
Marek Figlerowicz
Paweł P. Jagodziński
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-05777-6

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.